March 30, 2023
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Institute of Allergy and Infectious Diseases (NIAID)
National Eye Institute (NEI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Drug Abuse (NIDA)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAIDs interest in supporting research aimed at a collaboration between recipients funded via the Radiation and Nuclear Countermeasures Program ( RNCP ) and Chemical Countermeasures Research Program ( CCRP ). These collaborations between RNCP- and CCRP-supported researchers will generate data that can be leveraged for new medical countermeasures (MCMs) discovery and early development funding and enhance the state-of-the-science in both research areas.
The RNCP and CCRP were established by NIAID in 2004 and 2006, respectively, to support the discovery and early development of MCMs to mitigate and/or prevent the serious morbidities and mortalities that may occur after a mass casualty civilian radiation/nuclear or chemical incident. Components of both programs include early-stage fundamental and applied research, preclinical product development support service cores, and targeted research project grant and cooperative agreement initiatives.
The RNCP is focused on:
The CCRP is focused on discovery and early development of MCMs against almost 200 highly toxic chemicals that have been designated by the Department of Homeland Security as public health Chemicals of Concern (CoC). Examples of CoC include:
Injuries caused by acute radiation, such as bone marrow myelosuppression, organ fibrosis, acute and delayed lung and skin injuries, acute respiratory distress syndrome, coagulopathy, neurodegeneration, and neovascularization, may manifest similar or identical to conditions observed after chemical exposure and vice versa. As such, the multidisciplinary nature of radiation and chemical injury research potentially lends itself to the establishment of formal partnerships between RNCP- and CCRP-supported researchers. These RNCP-CCRP partnerships would allow leveraging of unique expertise, in vitro and in vivo, small, and large animal models, ex vivo organ systems, specialized exposure facilities, and other core competencies that have been cultivated under the two NIH initiatives.
The scientific scope of research supported by this Notice of Special Interest include, but are not limited to:
The proposed collaborative activities must be within the scope of the approved aims of the parent award and are expected to generate important new and mutually beneficial opportunities for achieving the goals of the parent project and those of the collaborator. Both collaborating parties may submit applications for concurrent consideration provided the proposed efforts are distinct.
The proposed supplement project must focus on addressing adverse health outcomes after a single acute exposure event; therefore, research on prolonged, persistent, or chronic environmental exposures are not within the scope of this NOSI. Note that clinical trials are not allowed. Applications nonresponsive to the terms of this NOSI will not be considered for award.
Administrative supplements can be used to meet costs associated with increased animal needs and personnel to carry out the proposed work. Applicants should propose research that, if successful, would help to enhance understanding of the overlap between chemical and radiation-induced pathways for injury, advance biomarkers in both mission spaces, or advance MCMs along the product development pathway, and contribute to the nation's medical and public health preparedness for, response to, and recovery from public health radiation or chemical emergencies.
Applicants are strongly encouraged to discuss their proposed supplement project with the NIAID/RNCP or NIAID/CCRP Program Official of the approved parent award prior to submission of a supplement application to ensure that the proposed activity is within the scientific priorities of the programs and the scope of the approved award.
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:
Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:
Scientific/Research Contact
Merriline Vedamony, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-5432
Email: merriline.satyamitra@nih.gov
Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-796-7237
Email: dy70v@nih.gov
Houmam H. Araj, Ph.D.
National Eye Institute (NEI)
Telephone: 301-435-8166
Email: ha50c@nih.gov
Alexey Belkin, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-827-6475
E-mail: alexey.belkin@nih.gov
Kiran RV. Vemuri, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-4446
E-mail: kiran.vemuri@nih.gov
Shardell M. Spriggs, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-443-8189
E-mail: shardell.spriggs@nih.gov
Financial/Grants Management Contact
Tamia Powell
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2982
Email: tamia.powell@nih.gov
Karen Robinson Smith
National Eye Institute (NEI)
Telephone: 301-435-8178
E-mail: kyr@nei.nih.gov
Sheila Simmons
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-594-9812
E-mail: simmonss@mail.nih.gov
Pamela G. Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
E-mail: pfleming@mail.nih.gov